Unity Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Unity Biotechnology
UBX Stock  USD 1.24  0.03  2.48%   
Unity Biotechnology financial statements provide useful quarterly and yearly information to potential Unity Biotechnology investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Unity Biotechnology financial statements helps investors assess Unity Biotechnology's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Unity Biotechnology's valuation are summarized below:
Gross Profit
-35.2 M
Market Capitalization
20.9 M
Enterprise Value Revenue
29.7906
Earnings Share
(1.28)
Quarterly Revenue Growth
(1.00)
We have found one hundred twenty available fundamental trend indicators for Unity Biotechnology, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Unity Biotechnology current market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 28.4 M in 2024. Enterprise Value is likely to drop to about 66.2 M in 2024

Unity Biotechnology Total Revenue

236,000

Check Unity Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Unity Biotechnology's main balance sheet or income statement drivers, such as Interest Income of 3.3 M, Depreciation And Amortization of 1.5 M or Interest Expense of 1.9 M, as well as many indicators such as Price To Sales Ratio of 104, Dividend Yield of 0.0 or PTB Ratio of 1.07. Unity financial statements analysis is a perfect complement when working with Unity Biotechnology Valuation or Volatility modules.
  
Check out the analysis of Unity Biotechnology Correlation against competitors.
For more information on how to buy Unity Stock please use our How to Invest in Unity Biotechnology guide.

Unity Biotechnology Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets100.2 M65.7 M112.2 M
Pretty Stable
Other Current Liabilities5.5 M3 M5.1 M
Slightly volatile
Total Current Liabilities14.3 M7.8 M9.4 M
Slightly volatile
Other Liabilities25.1 K26.4 K3 M
Slightly volatile
Property Plant And Equipment Net19.9 M18.1 M11.8 M
Slightly volatile
Accounts Payable2.1 M1.4 M1.9 M
Slightly volatile
Cash23.3 M19.8 M52.8 M
Slightly volatile
Non Current Assets Total25.2 M19.1 M15.2 M
Slightly volatile
Non Currrent Assets Other981.1 K1 M1.1 M
Very volatile
Other Assets992.6 K853.2 K1.1 M
Pretty Stable
Cash And Short Term Investments79.8 M43.2 M94.2 M
Very volatile
Common Stock Total Equity1.1 K1.1 K1.9 K
Pretty Stable
Common Stock Shares Outstanding15.5 M14.8 M4 M
Slightly volatile
Liabilities And Stockholders Equity100.2 M65.7 M112.2 M
Pretty Stable
Non Current Liabilities Total33 M29.5 M78 M
Slightly volatile
Capital Surpluse636.4 M606.1 M228 M
Slightly volatile
Other Current Assets2.1 M1.8 M3.2 M
Slightly volatile
Other Stockholder Equity355.1 M512.8 M196.1 M
Slightly volatile
Total Liabilities43.4 M37.3 M87.1 M
Slightly volatile
Property Plant And Equipment Gross17.9 M27.3 M10.8 M
Slightly volatile
Preferred Stock Total Equity167.8 M200 M155.3 M
Slightly volatile
Total Current Assets81.9 M46.6 M97.4 M
Pretty Stable
Common Stock3.7 K2 K2.4 K
Slightly volatile
Property Plant Equipment16.9 M9 M9.8 M
Slightly volatile
Net Receivables1.2 M1.6 M998.6 K
Slightly volatile
Long Term Debt Total9.8 M12.5 M6.3 M
Slightly volatile
Net Invested Capital27 M28.4 M89.3 M
Slightly volatile
Non Current Liabilities Other32.6 M31 M10.8 M
Slightly volatile
Net Working Capital71.5 M38.8 M84.3 M
Pretty Stable
Short and Long Term Debt Total33.9 M27 M14.7 M
Slightly volatile
Deferred Long Term Liabilities8.7 M15.3 M6.6 M
Slightly volatile
Capital Stock3.1 K2 K3.9 K
Pretty Stable
Short Term Debt6.2 M3.5 M2.3 M
Slightly volatile
Long Term Debt14.3 M9.8 M21.5 M
Slightly volatile
Capital Lease Obligations26.1 M27 M36.4 M
Slightly volatile
Short and Long Term Debt6.9 M10.9 M4.3 M
Slightly volatile

Unity Biotechnology Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income3.3 M3.2 M2.1 M
Very volatile
Selling General Administrative18.9 M18.8 M12.5 M
Slightly volatile
Other Operating Expenses67 M44.7 M44.5 M
Slightly volatile
Research Development34.4 M20.1 M30.7 M
Slightly volatile
Cost Of Revenue14.1 M19.7 M15.8 M
Very volatile
Total Operating Expenses67 M44.7 M44.5 M
Slightly volatile
Reconciled Depreciation2.5 M1.4 M1.8 M
Slightly volatile
Non Recurring2.1 M2.4 M2.6 M
Slightly volatile
Selling And Marketing Expenses625.6 K703.8 K766.4 K
Slightly volatile

Unity Biotechnology Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation9 M7.4 M5.1 M
Slightly volatile
Begin Period Cash Flow22 M12.7 M16.5 M
Slightly volatile
Depreciation2.2 M1.2 M1.3 M
Slightly volatile
Capital Expenditures10.4 K11 K1.4 M
Slightly volatile
End Period Cash Flow23.9 M19.8 M53.5 M
Slightly volatile
Change To Netincome11.6 M10.2 M11.3 M
Pretty Stable
Dividends Paid23.1 K24.3 K36.5 M
Slightly volatile
Issuance Of Capital Stock4.9 M5.1 M93.1 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio10499.2147.5364
Slightly volatile
Days Sales Outstanding291327356
Slightly volatile
Stock Based Compensation To Revenue37.5635.779.3529
Slightly volatile
Capex To Depreciation0.00880.00937.0303
Slightly volatile
EV To Sales24323173.6619
Slightly volatile
Payables Turnover14.9914.27463.4048
Slightly volatile
Sales General And Administrative To Revenue83.8879.8921.8323
Slightly volatile
Average Inventory0.40.450.49
Slightly volatile
Research And Ddevelopement To Revenue14814146.185
Slightly volatile
Capex To Revenue0.620.470.7625
Slightly volatile
Cash Per Share2.782.9243147
Slightly volatile
Days Payables Outstanding24.2925.56981.2 K
Slightly volatile
Income Quality0.640.93050.6837
Slightly volatile
Current Ratio10.695.944516.0222
Slightly volatile
Receivables Turnover0.80.90.9837
Slightly volatile
Graham Number10.2610.8028319
Slightly volatile
Debt To Equity0.260.270.2965
Very volatile
Capex Per Share7.0E-47.0E-43.4397
Slightly volatile
Revenue Per Share0.02720.02862.3782
Slightly volatile
Interest Debt Per Share2.632.272.1682
Slightly volatile
Debt To Assets0.130.150.156
Pretty Stable
Days Of Payables Outstanding24.2925.56981.2 K
Slightly volatile
Ebt Per Ebit1.170.89241.2884
Slightly volatile
Long Term Debt To Capitalization0.220.160.2178
Slightly volatile
Total Debt To Capitalization0.190.210.2273
Pretty Stable
Debt Equity Ratio0.260.270.2965
Very volatile
Quick Ratio10.75.944516.0237
Slightly volatile
Net Income Per E B T0.770.870.9122
Pretty Stable
Cash Ratio4.762.525912.3005
Slightly volatile
Days Of Sales Outstanding291327356
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.131.00031.0794
Slightly volatile
Fixed Asset Turnover0.00960.01010.1487
Slightly volatile
Debt Ratio0.130.150.156
Pretty Stable
Price Sales Ratio10499.2147.5364
Slightly volatile
Asset Turnover0.00210.00220.0179
Very volatile
Operating Cycle379373353
Slightly volatile

Unity Biotechnology Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap28.4 M29.9 M206.5 M
Slightly volatile
Enterprise Value66.2 M69.7 M245.4 M
Slightly volatile

Unity Fundamental Market Drivers

Cash And Short Term Investments43.2 M

Unity Upcoming Events

20th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
20th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Unity Biotechnology Financial Statements

Unity Biotechnology investors use historical fundamental indicators, such as Unity Biotechnology's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Unity Biotechnology. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue248.4 K236 K
Cost Of Revenue19.7 M14.1 M
Stock Based Compensation To Revenue 35.77  37.56 
Sales General And Administrative To Revenue 79.89  83.88 
Research And Ddevelopement To Revenue 140.56  147.59 
Capex To Revenue 0.47  0.62 
Revenue Per Share 0.03  0.03 
Ebit Per Revenue(280.54)(266.51)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
GOOGAlphabet Inc Class C
GOOGAlphabet Inc Class C

Additional Tools for Unity Stock Analysis

When running Unity Biotechnology's price analysis, check to measure Unity Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unity Biotechnology is operating at the current time. Most of Unity Biotechnology's value examination focuses on studying past and present price action to predict the probability of Unity Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unity Biotechnology's price. Additionally, you may evaluate how the addition of Unity Biotechnology to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY